Stay updated on JAK1 Inhibitor With Topical Therapy Clinical Trial

Sign up to get notified when there's something new on the JAK1 Inhibitor With Topical Therapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the JAK1 Inhibitor With Topical Therapy Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    Major update: page version bumped to v3.2.0 and a government funding operating-status notice added; previous v3.0.2 revision removed.
    Difference
    1%
    Check dated 2025-10-02T01:19:54.000Z thumbnail image
  5. Check
    27 days ago
    Change Detected
    Summary
    Version bumped from v3.0.2 to v3.1.0; no other substantive content changes detected.
    Difference
    0.0%
    Check dated 2025-09-30T13:59:47.000Z thumbnail image
  6. Check
    34 days ago
    Change Detected
    Summary
    Removed several MedlinePlus drug-safety and drug-quality topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs). This narrows the page’s scope and removes key informational topics.
    Difference
    0.1%
    Check dated 2025-09-23T10:27:59.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Summary
    Page version updated to v3.0.2 (from v3.0.1) and the 'Back to Top' link removed; the rest of the content remains unchanged.
    Difference
    0.1%
    Check dated 2025-09-16T05:11:24.000Z thumbnail image
  8. Check
    48 days ago
    Change Detected
    Summary
    The page has updated the citation for a study on Abrocitinib in adolescents with atopic dermatitis, reflecting a new version and publication date.
    Difference
    0.2%
    Check dated 2025-09-09T00:48:46.000Z thumbnail image
  9. Check
    55 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of new facility names and locations, particularly in Mexico, the United States, and various cities in Europe and Asia. Additionally, new drug information related to Abrocitinib has been included, enhancing the content's relevance and accuracy.
    Difference
    5%
    Check dated 2025-09-01T20:49:47.000Z thumbnail image

Stay in the know with updates to JAK1 Inhibitor With Topical Therapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the JAK1 Inhibitor With Topical Therapy Clinical Trial page.